Clinical Trial Details
— Status: Active, not recruiting
Administrative data
NCT number |
NCT05071547 |
Other study ID # |
2010/186-31 |
Secondary ID |
|
Status |
Active, not recruiting |
Phase |
Phase 2
|
First received |
|
Last updated |
|
Start date |
November 1, 2010 |
Est. completion date |
December 31, 2022 |
Study information
Verified date |
September 2021 |
Source |
Linkoeping University |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The aim of this feasibility study is to investigate if an addition of an internet-delivered
psychological treatment, Acceptance and commitment therapy (IACT), can enhance the effect of
an existing evidence-based interdisciplinary rehabilitation program (IRPR) for chronic pain
patients enrolled in clinical tertiary care, on pain-related psychological outcomes. The
study might contribute to developing internet-delivered treatments suitable for this patient
group and also help develop implementation strategies for internet interventions in clinical
services. The study is planned to run for 2 years and include 300 patients, of which 150 will
be in the intervention group and 150 in the control condition.
The overall hypothesis is that the IACT addition will lead to better and more sustained
results compared to the IRPR alone. The first sub-hypothesis is that the IACT addition will
enhance adherence and uptake during the IRPR. The second sub-hypothesis is that the IACT
addition will help patients maintain results after the IRPR has ended.
Description:
The trial is an un-blinded single-center randomized controlled trial with two parallel study
groups set at a clinical service in regular care at a University Hospital. An online true
random-number service (www.random.org) executed by a research assistant not otherwise
involved in the trial, will allocate participants, with 1:1 allocation ratio, upon
enrollment. Patients will be recruited from a specialist pain clinic which provides tertiary
care (IPRP) for non-malign chronic pain with mild to moderate psychiatric comorbidities and
serves as competence center for complex chronic pain in its City Council in southern Sweden.
As an active comparator will be used as the control condition, an effect size of d=0.30
(specific component comparator was expected. Given 80 % power and a 5% significance level,
the sample size calculation indicated that 90 participants in each group were needed.
Considering a 50% dropout rate, a sample size of 135 participants in each group would be
sufficient. The study planned to include n=300. Outcome variables will be collected digitally
on 4 occasions; at pre and post treatment, at post aftercare intervention and at 1 year
follow up. Additional complementary pen-and-paper data will be drawn from a national register
(the SQRP) at three occasions; at pre-baseline/enrollment, at post treatment and at 1 year
follow up. Outcome measures include psychological outcomes: pain acceptance, psychological
inflexibility, self-efficacy, harm/negative effects and psychosocial consequences of living
with pain. Also, measures of cost-effectiveness, usability, dose and time spent will be
collected. Patients with long pain duration, high pain intensity, overuse of analgesics,
alcohol or opioids, social withdrawnness, depression, or previous treatment failures
constitute high risk of attrition. Early signs of attrition will be monitored by delayed
response frequency. A plan to prevent attrition will be set at the inclusion assessment. As
long as participant follow the IPRP through, data will likely be collected and there will be
opportunities to discuss or prevent drop-out. Data will be entered and stored digitally. The
process is monitored by a responsible research assistant who will also alert the research
time of missing data. Access to study data will be restricted to the research team.The two
study arms will be compared using parametric methods for data analysis or other methods
depending on the robustness of the data. Missing data will be handled depending on the
robustness of the data, assessed by Little MCAR test. Intention to treat analysis is an
opportunity given the missing is not more than 40 %. Mixed models may be an option given
missing data is not random. The steering committee will act as data monitoring committee (the
lead investigator excluded) and will decide of interim analyses and execute stopping
guidelines. The research assistant responsible for data management will alert the steering
committee if collected data on negative experiences of treatment signals that any participant
needs additional care related to experiences of the trial. Any modifications to the protocol
which may impact on the study, will be agreed on within the research group. These changes
will be either documented to be addressed at publication or communicated with the regional
Ethical board if needed. Written informed consent will be obtained as pre-measurement are
collected. An oral consent will be obtained prior to that, during the assessment interview,
whereas participants may ask for further information. All recruited participants will be
given an identification number. As little personal information as possible (e.g. only
informed consent forms) will be kept locally as the majority of participants' information
will be digital, secured with password-protected access systems. The research team members
will be given access to the cleaned data set. To ensure confidentiality, data dispersed to
project team members will be blinded of any identifying participant information. The steering
committee will have access to the un-cleaned data set. Post-trial care will be given by IPRP
staff when needed.